Pharmaceutical formulations and methods of using thereof for the treatment and prevention of pulmonary arterial hypertension are provided. The formulations contain one or more agents to simultaneously reduce ADMA levels in a patient and reduce inflammatory processes in the pulmonary vasculature of a patient. The formulations contain a therapeutically effective amount of cerivastatin a cerivastatin analog or a pharmaceutically acceptable salt prodrug clathrate or solvate thereof in a carrier suit...

Abstract - 603255 Disclosed is the compound 2-(3-(cyclopropylmethyl)-2-oxo-imidazolidin-1-yl)-4-methyl-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide or a pharmaceutically acceptable salt thereof. Further disclosed is a pharmaceutical composition comprising a therapeutically effective amount of the compound 2-(3-(cyclopropylmethyl)-2-oxoimidazolidin-1-yl)-4-methyl-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide or a pharmaceutically acceptable salt thereof optionally in combination with a therapeutic...

Pharmaceutical formulations and methods of using thereof for the treatment and prevention of pulmonary arterial hypertension are provided. The formulations contain one or more agents to simultaneously reduce ADMA levels in a patient and reduce inflammatory processes in the pulmonary vasculature of a patient. The formulations contain a therapeutically effective amount of cerivastatin, a cerivastatin analog, or a pharmaceutically acceptable salt, prodrug, clathrate, or solvate thereof in a carrier...

Pharmaceutical formulations and methods of using thereof for the treatment and prevention of pulmonary arterial hypertension are provided. The formulations contain one or more agents to simultaneously reduce ADMA levels in a patient and reduce inflammatory processes in the pulmonary vasculature of a patient. The formulations contain a therapeutically effective amount of cerivastatin, a cerivastatin analog, or a pharmaceutically acceptable salt, prodrug, clathrate, or solvate thereof in a carrier...

PURPOSE: A pharmaceutical composition containing a statin-based drug and Wnt signal transduction regulator is provided to suppress MMP-9 expression and to prevent or treat arteriosclerosis and stroke. CONSTITUTION: A pharmaceutical composition for preventing or treating arteriosclerosis and stroke contains a statin-based drug and Wnt signal transduction regulator as active ingredients. The statin-based drug is selected from the group consisting of simvastain atorvastatin pravastatin pitavastatin...

Statin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for treating and/or preventing several diseases in particular coronary syndromes neurodegenerative disorders as well as for reducing cholesterol levels.

FIELD: chemistry. ^ SUBSTANCE: invention relates to novel statin derivatives of formula: or its pharmaceutically acceptable salt or stereoisomer where: X represents -O- R represents statin residue of formula: ^ ^ ^ Y represents a) straight or branched C1-C20alkylene mainly C1-C10 optionally substituted with one or more OH; ^ b) ^ ^ where n equals from 0 to 20 and n1 from 1 to 20; on condition that when Y represents b) group -ONO2 is bonded with -(CH2)nÇè1; ^ g) ^ ^ where X2 represents -O n3 f...